Pierre Fabre Laboratories Expands Cancer R&D With Acquisition of Two Promising Lung Cancer Drug Candidates
French pharmaceutical group Pierre Fabre Laboratories has acquired the worldwide rights to two next-generation therapies for non-small cell lung cancer (NSCLC), strengthening its oncology research and development pipeline. Pierre Fabre Laboratories announced today the acquisition of global rights to PFL-721 and PFL-241—formerly STX-721 and STX-241—from Antares Therapeutics, a spin-out of U.S.-based Scorpion Therapeutics. The two…
